Page 50 - JCTR-9-6
P. 50

Journal of Clinical and Translational Research 2023; 9(6): 414-422




                                        Journal of Clinical and Translational Research

                                               Journal homepage: http://www.jctres.com/en/home


        ORIGINAL ARTICLE

        Biocompatibility of calcitonin receptor fragment peptide-treated

        3D-printed bone scaffolds: a muscle pouch implantation study



        Vamiq M. Mustahsan  Yanming Cai , David E. Komatsu , Imin Kao , Srinivas Pentyala *
                          1,3,
                                        3
                                                          2
                                                                   3
                                                                                     1,2
        1 Department of Anesthesiology, Stony Brook University Renaissance School of Medicine, Stony Brook, 11794, NY, United States of America,
        2 Department of Orthopaedics and Rehabilitation and Stony Brook University Renaissance School of Medicine, Stony Brook, 11794, NY, United States
        of America,  Department ofMechanical Engineering Stony Brook University College of Engineering and Applied Sciences, Stony Brook, 11794, NY,

                3
        United States of America
        ARTICLE INFO                        ABSTRACT
        Article history:                    Background and Aim: Current synthetic bone graft substitutes (BGSs) in development are limited by
        Received: August 07, 2023           high resorption, poor load-bearing properties, and stress shielding. These limitations inhibit BGS from
        Revised: September 26, 2023         complete biointegration. In this study, we developed calcitonin receptor fragment peptide (CRFP)-
        Accepted: October 03, 2023          treated  non-biodegradable  MED610  scaffold,  seeded  with  MC3T3  stem  cells,  and  assessed  their
        Published online: November 18, 2023  in vivo biocompatibility and biointegration.
                                            Methods: Scaffolds were fabricated with Stratasys MED610 (MED610) material, seeded with Mus
        Keywords:                           musculus calvaria cells (MC3T3), and osteogenesis was induced with CRFP after the cells reached
        Calcitonin receptor fragment peptide  confluency and generated bone matrix. Scaffolds with and without bone matrix were implanted in
        Osteogenic peptide                  male mice following a muscle pouch implantation protocol. Post-extraction, imaging, staining, and
        ABS                                 mechanical compression testing was carried after 3 weeks of scaffold implantation in the muscle to
        MED610                              measure the ectopic bone formation and compressive strength.
        Scaffolds                           Results:  The  implanted  scaffolds  showed  significantly  higher  (P < 0.01) calcium  deposits in
        3D printing                         comparison to the untreated scaffolds. We also found significantly higher (P < 0.001) mineralization
        Muscle pouch                        on the implanted scaffolds compared to scaffolds before implantation. The mechanical properties of
                                            the scaffolds did not vary significantly.
        *Corresponding author:              Conclusions: MED610 scaffolds treated with CRFP in vivo do not cause any adverse reaction when
        Srinivas Pentyala                   implanted in muscle and showed significant ectopic bone formation, indicating biocompatibility and
        Anesthesiology, HSC L4, Room: 060,   bio-integration.
        Renaissance School of Medicine, Stony Brook,   Relevance for Patients: This study will aid in developing biomimetic and biocompatible artificial
        NY, 11794-8480, United States of America.  bones for implantation.
        Tel: +1 631-444-2974
        Fax: +1 631-444-2907
        Email: Srinivas.pentyala@stonybrook.edu
                                            1. Introduction
        © 2023 Author(s). This is an Open-Access
        article distributed under the terms of the   In many orthopedic surgical procedures, metallic implants are used to fill in the defects
        Creative Commons Attribution-Noncommercial   formed due to surgery or fracture [1-3]. Metallic implants are strong and are able to withstand
        License, permitting all non-commercial use,   the load experienced by the bone. However, metallic implants lead to stress shielding and,
        distribution, and reproduction in any medium,   hence, weaken the surrounding bone [4]. Moreover, metallic implants are inert to bone
        provided the original work is properly cited.
                                            growth and inhibit complete implant integration [5]. The alternative for metallic implants
                                            is biological implants vis, autografts and allografts [6]. Autografts are osteoconductive and
                                            promote bio integration of the implant as they are extracted from the subject’s body [7].
                                            They also have a lower rate of disease transmission in comparison to allografts. However,
                                            autografts have other complications vis, lower availability, excessive pain, and increased
                                            hospitalization cost due to extraction surgery [8,9]. Allografts exhibit reduced operating

                                           DOI: http://dx.doi.org/10.18053/jctres.09.202306.23-00097
   45   46   47   48   49   50   51   52   53   54   55